Ono Venture Investment, Inc.

Ono Venture Investment, Inc. (OVI) is the corporate venture capital arm of Ono Pharma, an R&D-oriented pharmaceutical company succeeded in delivery of “First in class” medicines to patients such as OPDIVO® (nivolumab).